

Amendment to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims

1. (currently amended) A method for reducing a wrinkle, the method comprising the step of administering an amount of a botulinum toxin in powder form effective to reduce a wrinkle of a human subject using a needleless syringe, thereby reducing the wrinkle.
2. (previously presented) The method of claim 1 wherein the botulinum toxin is administered with a carrier.
3. (previously presented) The method of claim 2 wherein the botulinum toxin is coated on said carrier.
4. (previously presented) The method of claim 2 wherein said carrier comprises a material selected from the group consisting of gold, platinum, tungsten and ice crystal.
- 5-9. (cancelled)
10. (previously presented) The method of claim 1 wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C₁, D, E, F and G.
11. (cancelled)
12. (previously presented) The method of claim 1 wherein the botulinum toxin is toxin type A.

13-35. (cancelled)

36. (currently amended) A method for treating brow furrows in a human subject, the method comprising the step of administering a brow-furrow reducing amount of a botulinum toxin in powder form to the human subject using a needleless syringe having a pressure sufficient to deliver the botulinum toxin to a muscle tissue associated with the brow furrows so as to reduce a muscle contraction of the muscle tissue, thereby ~~reducing~~ treating the brow furrows.

37. (previously presented) The method of claim 36, wherein the botulinum toxin is administered with a carrier.

38. (previously presented) The method of claim 37, wherein the botulinum toxin is coated on said carrier.

39. (previously presented) The method of claim 37, wherein said carrier comprises a material selected from the group consisting of gold, platinum, tungsten and ice crystal.

40-42. (cancelled)

43. (previously presented) The method of claim 36, wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C₁, D, E, F and G.

44. (previously presented) The method of claim 36, wherein the botulinum toxin is toxin type A.

45. (currently amended) A method for treating a wrinkle on a human face, the method comprising the step of administering a wrinkle reducing amount of a

botulinum toxin in powder form to a subdermal muscle tissue in proximity to the wrinkle using a needleless syringe having a pressure sufficient to deliver the botulinum toxin to the subdermal muscle tissue associated with the wrinkle so as to reduce a muscle contraction of the muscle tissue, thereby ~~reducing~~ treating the wrinkle.

46. (currently amended) A method for treating a wrinkle on a human face, the method comprising the step of administering a wrinkle reducing amount of powdered botulinum toxin to a subdermal muscle tissue in proximity to the wrinkle using a needleless syringe connected to or connectable to means for producing a supersonic gas flow and having a pressure sufficient to deliver the powdered botulinum toxin to the subdermal muscle tissue associated with the wrinkle so as to reduce a muscle contraction of the muscle tissue, thereby ~~reducing~~ treating the wrinkle.

47. (previously presented) The method of claim 46 wherein the means for producing a supersonic gas flow is a burst of helium.

48. (new) A method for treating a dermal wrinkle, the method comprising the step of administering an amount of a botulinum toxin type A in powder form effective to reduce a dermal wrinkle of a human subject using a needleless syringe, thereby treating the dermal wrinkle.